Don's practice focuses on preparing and prosecuting domestic and international patent applications for clients in the pharmaceutical, chemical, and biotechnology industries. Don also assists clients on IP matters, including non-infringement and invalidity opinions, freedom-to-operate, litigation strategy, due diligence, Hatch-Waxman/ANDA litigation, and strategic patent portfolio reviews.
For clients in the pharmaceutical and chemical industries, Don advises on and prosecutes patents for anticancer therapeutics, kinase inhibitors, chemoprotection agents, infectious disease therapeutics, antivirals, anti-inflammatory agents, polymers, pharmaceutical formulations, insecticides, and agrochemicals. For clients in the life science and biotechnology industries, Don’s experience includes therapeutic antibodies, recombinant protein therapeutics, RNAi therapeutics, gene therapy, human vaccines, veterinary vaccines, and in vitro diagnostics.
Prior to becoming an attorney, Don spent several years with the Centers for Disease Control and Prevention (CDC) as a Licensing Associate with the Technology Transfer Office, where he drafted and negotiated intellectual property licenses with industry partners ranging from small biotechnology start-ups to major multi-national pharmaceutical corporations. During his tenure at the CDC, Don attended Georgia State University College of Law, where he was the recipient of the Intellectual Property Scholarship, an Associate Editor for the Georgia State University Law Review, and graduated with honors (magna cum laude).
Don began his studies in Chemistry at Eckerd College, where he was awarded the Presidential Scholarship, had a 4.0 GPA, was named the Outstanding Student in Natural Sciences and was given the Mark J. Ferguson Award for Outstanding Student in Chemistry. Don continued his studies at Harvard University where he received his PhD in Genetics. While at Harvard, his thesis, "Characterization of the transcription elongation factors Elf1 and TFIIS in S. cerevisiae" focused on the mechanisms of gene regulation and the role of novel transcription elongation factors in regulating gene expression.
Memberships and Affiliations
- Member, Atlanta Intellectual Property Inn of Court
- Member, Georgia Bar Intellectual Property Section
- Prather DM. Patentable Subject Matter: "Banking" on Supreme Uncertainty. Connecticut Intellectual Property Law Association. March 26, 2014.
- Zhang L, Prather DM, Vanden Eng J, Crawford S, Kariuki S, ter Kuile F, Terlouw D, Nahlen B, Lal AA, Slutsker L, Udhayakumar V, Shi YP. Polymorphisms in genes of interleukin 12 and its receptors and their association with protection against severe malarial anaemia in children in western Kenya. Malar J. 2010 Mar 29;9:87.
- Prather DM, Krogan NJ, Emili A, Greenblatt JF, Winston F. Identification and characterization of Elf1, a conserved transcription elongation factor in Saccharomyces cerevisiae. Mol Cell Biol. 2005 Nov;25(22). 10122-35.
- Parther DM, Larschan E, Winston F. Evidence that the elongation factor TFIIS plays a role in transcription initiation at GAL1 in Saccharomyces cerevisiae. Mol Cell Biol. 2005 Apr;25(7): 2650-9.
- Yoder JA, Mueller MG, Wei S, Coliss BC, Prather DM, Willis T, Litman RT, Djeu JY, Litman GW. Immune-type receptor genes in zebrafish share genetic and functional properties with genes encoded by the mammalian leukocyte receptor cluster. Proc Natl Acad Sci USA. 2001 Jun5;98(12):6771-6
- Associate, Knowles Intellectual Property Strategies, LLC
- Licensing Associate, Centers for Disease Control and Prevention